Regencell Bioscience (NASDAQ:RGC) Stock Price Up 6.5% - Should You Buy?

Key Points

• Shares jumped 6.5% intraday to $25.72 (from $24.15) but on very thin trading — 36,822 shares, about 91% below the average daily volume of 422,797.
• Analyst sentiment is negative: Weiss Ratings reiterated a "sell (e+)" and MarketBeat lists the stock's average rating as "Sell."
• Institutional activity is mixed: Geode Capital massively increased its stake and several firms opened positions, yet institutions collectively own just 0.13% of the company, which develops TCM-based treatments for neurocognitive disorders like ADHD and autism.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) shares traded up 6.5% during mid-day trading on Thursday . The company traded as high as $26.30 and last traded at $25.7150. 36,822 shares changed hands during trading, a decline of 91% from the average session volume of 422,797 shares. The stock had previously closed at $24.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of "Sell".

Regencell Bioscience Price Performance

The stock's 50 day simple moving average is $27.05 and its 200 day simple moving average is $21.21.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RGC. Geode Capital Management LLC increased its holdings in Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company's stock worth $6,664,000 after purchasing an additional 384,250 shares during the period. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets purchased a new position in shares of Regencell Bioscience during the second quarter valued at $768,000. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience during the third quarter valued at $598,000. Finally, Vident Advisory LLC raised its holdings in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock valued at $629,000 after acquiring an additional 11,866 shares in the last quarter. Institutional investors own 0.13% of the company's stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.